|Articles|October 2, 2003

ACT 2003 Winter Forum Conference Programme

Newsletter

Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.

Subscribe Now!

Related Content

© putilov_denis - © putilov_denis - stock.adobe.com

Our Top 5 Most Read Articles in 2025

ByAndy Studna, Senior Editor

December 24th 2025

© photon_photo - © photon_photo - stock.adobe.com

Controlled Clinical Trials in Sub-Saharan Africa: A Winning Value Proposition

ByDonald de Korte, Alan Boyce, and Karin Kanewske Turner

December 24th 2025

ACT Brief: FDA Approval of Oral Wegovy, 2025’s Most-Read ACT Coverage, and Data Quality as the Foundation for AI

ByAndy Studna, Senior Editor

December 24th 2025

FDA Approves Oral Wegovy Following Positive Phase III OASIS 4 Trial Results

ByAndy Studna, Senior Editor

December 23rd 2025

Measuring Whether Site Support Investments Are Actually Working

ByKevin Williams,Andy Studna, Senior Editor

December 23rd 2025

ACT 2003 Winter Forum Conference Programme

Newsletter

Related Content

Our Top 5 Most Read Articles in 2025

Controlled Clinical Trials in Sub-Saharan Africa: A Winning Value Proposition

ACT Brief: FDA Approval of Oral Wegovy, 2025’s Most-Read ACT Coverage, and Data Quality as the Foundation for AI

FDA Approves Oral Wegovy Following Positive Phase III OASIS 4 Trial Results

Measuring Whether Site Support Investments Are Actually Working

Trending on Applied Clinical Trials Online

FDA Approves Oral Wegovy Following Positive Phase III OASIS 4 Trial Results

Controlled Clinical Trials in Sub-Saharan Africa: A Winning Value Proposition

Our Top 5 Most Read Articles in 2025

FDA Approves Subcutaneous Lunsumio VELO Based on GO29781 Trial Results in Relapsed or Refractory Follicular Lymphoma

ACT Brief: FDA Approval of Oral Wegovy, 2025’s Most-Read ACT Coverage, and Data Quality as the Foundation for AI